je.st
news
Lannett Receives FDA Approval for Letrozole Tablets USP 2.5 mg
2014-10-30 13:22:43| Biotech - Topix.net
Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Letrozole Tablets USP, 2.5 mg, the therapeutic equivalent to the reference listed drug, FemaraA Tablets, 2.5 mg, of Novartis Pharmaceuticals Corporation. According to IMS, for the year ended September 2014 total sales of Letrozole Tablets USP, 2.5 mg, at Average Wholesale Price were approximately $359 million.
Tags: approval
mg
receives
tablets
Category:Biotechnology and Pharmaceuticals